Client News

OKYO Pharma Limited: Q4 ’22 IND planned followed by P2 with AmbioPharm
Home / Client News / OKYO Pharma Limited: Q4 ’22 IND planned followed by P2 with AmbioPharm

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

https://www.londonstockexchange.com/news-article/OKYO/q4-22-ind-planned-followed-by-p2-with-ambiopharm/15604189

​

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

APPLY NOW

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

LOGIN

Submit a Comment

Optiva Securities Ltd
7 Harp Lane
London EC3R 7DP

Tel +44 (0)20 3137 1902
info@optivasecurities.com
 optivasecurities
@optivalondon
Optiva Securities

KEEP UPDATED

Register to stay updated with the latest news.

    We would like to send you occasional emails about our services and keep you up to date with the latest announcements and news. To join our mailing list, simply click below. You can unsubscribe at any time.

    Optiva Securities Limited is authorised and regulated by the United Kingdom Financial Conduct Authority and are Members of the London Stock Exchange.

    © Copyright Optiva Securities Limited. Registered in England number 3068464
    Share This